Simulations Plus (SLP) Reports In-Line Q4 EPS, Misses on Revenue; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- SK Hynix's record profit misses forecasts, shares slump 10% despite robust AI chip demand
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Simulations Plus Reports Fourth Quarter and Fiscal 2025 Financial Results
December 1, 2025 4:05 PM ESTReaffirms fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10Â
Investor Day on January 21, 2026, to present new product vision and AI solutions
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (Simulations Plus or the Company), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025.
Fourth Quarter 2025 Financial Highlights (as compared to fourth quarter 2024)
Total revenue decreased 6% to... More